Company Of The Day: Roche

December 27th, 2021 by Trefis Team
+21.74%
Upside
34.50
Market
42.00
Trefis
RHHBY: Roche logo
RHHBY
Roche

What?

The U.S. FDA has granted Emergency Use Authorization for Roche (OTMKTS:RHHBY) at-home Covid-19 test, which uses a nasal swab and provides results in as little as 20 minutes.

So What?

Relevant Articles
  1. Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?
  2. Will Roche Stock Rebound To Its 2022 Highs of $50?
  3. Is Roche Stock Undervalued At $33?
  4. What’s Driving Roche Stock?
  5. Company Of The Day: Roche Holdings
  6. What’s Happening With Roche (RHHBY) Stock?

Covid-19 is providing quite difficult to contain despite the wide availability of vaccines and testing will likely remain key to keeping the broader economy open. For example, the U.S. government intends to start distributing 500 million at-home tests in January. This could potentially drive demand for Covid-19 test kits for companies including Roche.

See Our Complete Analysis For Roche

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Dec 2021
MTD [1]		 2021
YTD [1]		 2017-21
Total [2]
 RHHBY Return 7% 18% 81%
 S&P 500 Return 1% 26% 111%
 Trefis MS Portfolio Return 2% 47% 296%

[1] Month-to-date and year-to-date as of 12/27/2021
[2] Cumulative total returns since 2017

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates